BrainStorm Cell Therapeutics Inc. (BCLI) stock

BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30

$0.77−0.01 (-1.17%)

Close on Oct 19, 2026Market cap $8.50MP/E –Yield –

BrainStorm Cell Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

BrainStorm Cell Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?